John P A Ioannidis1. 1. Meta-Research Innovation Center at Stanford (METRICS), Stanford University, 1265 Welch Road, Stanford, California 94305, United States of America.
Abstract
OBJECTIVE: To estimate the infection fatality rate of coronavirus disease 2019 (COVID-19) from seroprevalence data. METHODS: I searched PubMed and preprint servers for COVID-19 seroprevalence studies with a sample size ≥ 500 as of 9 September 2020. I also retrieved additional results of national studies from preliminary press releases and reports. I assessed the studies for design features and seroprevalence estimates. I estimated the infection fatality rate for each study by dividing the cumulative number of COVID-19 deaths by the number of people estimated to be infected in each region. I corrected for the number of immunoglobin (Ig) types tested (IgG, IgM, IgA). FINDINGS: I included 61 studies (74 estimates) and eight preliminary national estimates. Seroprevalence estimates ranged from 0.02% to 53.40%. Infection fatality rates ranged from 0.00% to 1.63%, corrected values from 0.00% to 1.54%. Across 51 locations, the median COVID-19 infection fatality rate was 0.27% (corrected 0.23%): the rate was 0.09% in locations with COVID-19 population mortality rates less than the global average (< 118 deaths/million), 0.20% in locations with 118-500 COVID-19 deaths/million people and 0.57% in locations with > 500 COVID-19 deaths/million people. In people younger than 70 years, infection fatality rates ranged from 0.00% to 0.31% with crude and corrected medians of 0.05%. CONCLUSION: The infection fatality rate of COVID-19 can vary substantially across different locations and this may reflect differences in population age structure and case-mix of infected and deceased patients and other factors. The inferred infection fatality rates tended to be much lower than estimates made earlier in the pandemic. (c) 2021 The authors; licensee World Health Organization.
OBJECTIVE: To estimate the infection fatality rate of coronavirus disease 2019 (COVID-19) from seroprevalence data. METHODS: I searched PubMed and preprint servers for COVID-19 seroprevalence studies with a sample size ≥ 500 as of 9 September 2020. I also retrieved additional results of national studies from preliminary press releases and reports. I assessed the studies for design features and seroprevalence estimates. I estimated the infection fatality rate for each study by dividing the cumulative number of COVID-19 deaths by the number of people estimated to be infected in each region. I corrected for the number of immunoglobin (Ig) types tested (IgG, IgM, IgA). FINDINGS: I included 61 studies (74 estimates) and eight preliminary national estimates. Seroprevalence estimates ranged from 0.02% to 53.40%. Infection fatality rates ranged from 0.00% to 1.63%, corrected values from 0.00% to 1.54%. Across 51 locations, the median COVID-19 infection fatality rate was 0.27% (corrected 0.23%): the rate was 0.09% in locations with COVID-19 population mortality rates less than the global average (< 118 deaths/million), 0.20% in locations with 118-500 COVID-19 deaths/million people and 0.57% in locations with > 500 COVID-19 deaths/million people. In people younger than 70 years, infection fatality rates ranged from 0.00% to 0.31% with crude and corrected medians of 0.05%. CONCLUSION: The infection fatality rate of COVID-19 can vary substantially across different locations and this may reflect differences in population age structure and case-mix of infected and deceased patients and other factors. The inferred infection fatality rates tended to be much lower than estimates made earlier in the pandemic. (c) 2021 The authors; licensee World Health Organization.
Authors: Marina Pollán; Beatriz Pérez-Gómez; Roberto Pastor-Barriuso; Jesús Oteo; Miguel A Hernán; Mayte Pérez-Olmeda; Jose L Sanmartín; Aurora Fernández-García; Israel Cruz; Nerea Fernández de Larrea; Marta Molina; Francisco Rodríguez-Cabrera; Mariano Martín; Paloma Merino-Amador; Jose León Paniagua; Juan F Muñoz-Montalvo; Faustino Blanco; Raquel Yotti Journal: Lancet Date: 2020-07-06 Impact factor: 79.321
Authors: Kai Kisielinski; Paul Giboni; Andreas Prescher; Bernd Klosterhalfen; David Graessel; Stefan Funken; Oliver Kempski; Oliver Hirsch Journal: Int J Environ Res Public Health Date: 2021-04-20 Impact factor: 3.390
Authors: Jameson D Voss; Martin Skarzynski; Erin M McAuley; Ezekiel J Maier; Thomas Gibbons; Anthony C Fries; Richard R Chapleau Journal: Evol Med Public Health Date: 2021-06-27
Authors: Patrick Pietzonka; Erik Brorson; William Bankes; Michael E Cates; Robert L Jack; Ronojoy Adhikari Journal: PLoS One Date: 2021-11-24 Impact factor: 3.240
Authors: Javier M Moguerza; Salvador Perelló Oliver; Isaac Martín de Diego; Víctor Aceña; Carmen Lancho; Marina Cuesta; César González Fernández Journal: Int J Environ Res Public Health Date: 2021-05-18 Impact factor: 3.390
Authors: Ralf Wagner; David Peterhoff; Stephanie Beileke; Felix Günther; Melanie Berr; Sebastian Einhauser; Anja Schütz; Hans Helmut Niller; Philipp Steininger; Antje Knöll; Matthias Tenbusch; Clara Maier; Klaus Korn; Klaus J Stark; André Gessner; Ralph Burkhardt; Michael Kabesch; Holger Schedl; Helmut Küchenhoff; Annette B Pfahlberg; Iris M Heid; Olaf Gefeller; Klaus Überla Journal: Viruses Date: 2021-06-10 Impact factor: 5.048